3
TRANSACTIVATIONOFTHEHEPATITISBVIRUSCOREPROMOTERBYTHENUCLEARRECEPTORFXRΑ
(C.RAMIERE)................................................................................................................................................27
LEVIRUSDEL’HEPATITECINDUITLAFIBROSEHEPATIQUESANSINFLAMMATIONCHEZDESSOURIS
TRANSGENIQUESEXPRIMANTLATOTALITEDUCADREOUVERTDELECTUREVIRAL
(P.CHOUTEAU)............................................................................................................................................28
HEPATITISCVIRUSMODULATESHEPATOCYTEAPOPTOSISBYTARGETINGBID
(U.HIBNER)..................................................................................................................................................30
ANALYSEULTRASTRUCTURALEETQUANTITATIVEDESREGROUPEMENTSDEGOUTTELETTESLIPIDIQUES
INDUITSPARLAPROTÉINEDECOREDUVHC
(M.DEPLA)...................................................................................................................................................31
N‐TERMINALUBIQUITINATIONOFHEPATITISBVIRUSXPROTEIN
(S.BENHENDA).............................................................................................................................................33
LEROLEDURETROTRANSPORTDURETICULUMENDOPLASMIQUEVERSLECYTOPLASMEDELAPROTEINE
PRECOREDUVIRUSDEL’HEPATITEBHUMAINE
(M.DURIEZ).................................................................................................................................................34
HEPATITISCVIRUSNON‐STRUCTURALPROTEIN2DISTURBSTHESECRETORYPATHWAYANDITSEFFECTIS
COMPENSATEDBYTHEVIRALENVELOPEPROTEINS
(N.CALLENS)................................................................................................................................................35
HEPATITISCVIRUSINFECTIONPROTEINNETWORK
(B.DECHASSEY)...........................................................................................................................................36
INHIBITIONDRASTIQUEDESECRETIONDESHEPADNAVIRUSPARUNPEPTIDEPERMEABILISANT
(F.ABDUL)....................................................................................................................................................37
CARACTERISATIOND’UNENOUVELLEMUTATIONDERESISTANCE(V36C)CHEZUNPATIENTTRAITEAVECUNE
TRITHERAPIEDETELAPREVIR,D’IFN‐ALPHA2APEGYLEETDERIBAVIRINE
(L.BARBOTTE)..............................................................................................................................................38
EFFETANTIVIRALDUBAY41‐4109DANSUNMODELEANIMALHUMANISEETINFECTEPARLEVHB:LASOURIS
ALB‐UPA/SCID
(N.BREZILLON).............................................................................................................................................40
REACTIVATIONSOUSL’ASSOCIATIONFLUTICASONE‐RITONAVIRD'UNEINFECTIONAVHBOCCULTECHEZUN
PATIENTANTI‐HBS+ETCO‐INFECTEPARLEVIH
(A.KAY)........................................................................................................................................................41
NOUVELLESTRATEGIEANTIVIRALE:DESARNNEGATIFSCONTRELEVHC
(J.BITARD)...................................................................................................................................................43
HEPATITISCVIRUSIMPAIRSPLASMACYTOIDDENDRITICCELL‐ASSOCIATEDPRODUCTIONOFINTERFERON
ALPHA
(I.HIRSCH)....................................................................................................................................................44
UPTAKEANDTRAFFICKINGOFCELLCULTURE‐DERIVEDHEPATITISCVIRUS(HCVCC)INHUMAN
PLASMACYTOIDDENDRITICCELLS
(M.LAMBOTIN)............................................................................................................................................45
REPONSENEUTRALISANTEHUMORALECONTRELEVHCLORSDELACOINFECTIONPARLEVIHETDELA
TRANSPLANTATIONHEPATIQUE
(G.MAURIN)................................................................................................................................................47
CRITICALROLEOFINTRA‐HEPATICCD4+CD25+FOXP3+CELLSINHCVINFECTEDPATIENTS
(E.JOUVIN‐MARCHE)....................................................................................................................................49
ÉTUDEDEL’ENCAPSIDATIONDUGENOMEDUVHCPARMESUREDEL’INTERACTIONENTRELAPROTEINE
COREETL’ARNVIRALAUMOYEND’UNVECTEURLENTIVIRALEXVIVO
(E.PIVER).....................................................................................................................................................50